Navigation Links
NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009
Date:9/3/2009

FT. MYERS, Fla., Sept. 3 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it will present at the Rodman & Renshaw 11th Annual Healthcare Conference being held from September 9-11, 2009 at the New York Palace Hotel in New York City. The conference will showcase small and microcap public life sciences and biotech companies. Senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference.

NeoGenomics is scheduled to present on Thursday, September 10th at 3:40 PM EDT in the Fahnestock Salon on the fifth floor of the hotel. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq15/ngnm.ob. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
2. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
3. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
4. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
5. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
6. NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009
7. NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results
8. NeoGenomics Reports Second Quarter 2009 Results
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):